首頁 > 市場調查報告書 > 製藥

再生醫學

市場調查報告書

商品編碼

1616802

再生醫療的全球市場:產品，治療領域，各地區，2024年～2031年

Global Regenerative Medicine Market By Product, Therapeutic Area, & Region for 2024-2031

出版日期: 2024年11月16日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

再生醫學市場評估，2024-2031

大眾越來越認識到預防性和個人化醫療在控制癌症、中樞神經系統疾病等流行慢性疾病方面的益處，正在推動再生醫學市場的成長潛力。 Verified Market Research 的分析師表示，到 2031 年，再生醫學市場的價值將超過預期的 1,734.9 億美元，到 2024 年的營收將達到 327.1 億美元。

人口老化加劇導致的疾病負擔增加是再生醫學市場的主要驅動力。當前醫療保健格局變化的趨勢預計將隨著時間的推移而擴大，使市場從 2024 年到 2031 年的複合年增長率達到 23.19%。

再生醫學市場定義/概述

再生醫學是一個先進的醫學領域，專注於利用人體先天的癒合和修復能力。我們使用現代程序來刺激和替換受損的組織和器官，以恢復正常功能。一項重要的策略是使用幹細胞。幹細胞具有分化成多種細胞類型的獨特能力。在再生醫學中，科學家和醫生利用這些細胞來修復或替換因受傷、疾病或老化而受損的組織。

此外，治療心臟病和關節損傷、再生皮膚，甚至培養用於移植的器官只是再生醫學眾多應用中的一小部分。其目的是透過培養人體固有的治癒能力並為各種健康問題提供創造性的解決方案來改變醫療幹預措施。

慢性疾病的蔓延會導致再生醫學銷售量激增嗎？

隨著癌症、心血管疾病、神經系統疾病等盛行率的增加，需要特殊的醫療照護來解決根本原因並提供改變疾病甚至治癒的可能性。因此，慢性病的盛行率不斷增加，這是推動再生醫學市場成長的主要因素。

基因編輯、幹細胞工程和 3D 生物列印的快速進展將加速更有效和定製藥物的開發。這些突破將擴大可治療的疾病類型，提高治療準確性，改善患者的整體治療效果，並將再生醫學推向市場醫療保健主流。

此外，政府增加對藥物發現研究和開發的支持和資助對於再生醫學的擴張至關重要。創投、製藥公司和政府機構也提供了越來越多的財政支持，以提高此類護理的生產力。除此之外，製藥業的財務穩定性正在導致更快的臨床研究、更大的患者群體和更快的市場滲透，所有這些都促進了再生醫學市場的成長。

高昂的製造成本和複雜的製造流程如何影響再生醫學市場？

複雜的監管系統，加上細胞和基因療法的安全問題，使得審批過程既耗時又昂貴。因此，嚴格的監管和冗長的審批流程是限制再生醫學市場成長的障礙。

再生醫學市場面臨著巨大的製造和可擴展性挑戰，因為細胞和基因療法涉及高昂的製造成本和複雜的製造程序。所用生物成分的脆弱性加劇了挑戰，導致成本更高且患者接觸受限。

此外，這些治療的高昂成本限制了患者的治療並對醫療保健系統造成壓力。鑑於再生醫學的高昂前期成本和短期數據，不成熟的報銷政策和保險公司不願承擔費用是限制其採用的主要挑戰。

概要
北美
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲
亞太地區
- 中國
- 日本
- 印度
- 其他亞太地區
南美
- 巴西
- 阿根廷
- 其他的南美
中東·非洲
- 阿拉伯聯合大公國
- 沙烏地阿拉伯
- 南非
- 其他中東和非洲

第8章全球再生醫療市場:競爭情形

概要
各公司的市場排行榜
主要的開發策略
企業的地區足跡
企業的產業足跡
ACE矩陣

第9章企業簡介

Johnson & Johnson
Novartis
Roche
AbbVie
Pfizer
Vericel Corporation
Cellular Dynamics International
Editas Medicine
Spark Therapeutics
Bluebird bio

第10章主要發展

產品的上市/開發
合併和收購
事業擴大
夥伴關係和合作

第11章附錄

相關調查

簡介目錄

Product Code: 7157

Regenerative Medicine Market Valuation - 2024-2031

Growing public awareness regarding the benefits of preventative and personalized medicine in curbing prevalent chronic diseases such as cancer, central nervous diseases, and others drives the growth potential of the Regenerative Medicine Market. According to the analyst from Verified Market Research, the Regenerative Medicine Market is estimated to reach a valuation of USD 173.49 Billion by 2031, over the forecast by subjugating the revenue of USD 32.71 Billion valued in 2024.

The rising burden of diseases among the growing aging population is a key driver of the Regenerative Medicine Market. The current trend of shifting healthcare landscape is expected to grow over time enabling the market to grow at aCAGR of 23.19% from 2024 to 2031.

Regenerative Medicine Market: Definition/ Overview

Regenerative medicine is an advanced branch of medicine that focuses on using the body's natural ability to heal and repair itself. It involves using modern procedures to stimulate or replace damaged tissues and organs to restore normal function. One important strategy is the utilization of stem cells, which have the unique capacity to differentiate into diverse cell types. In regenerative medicine, scientists and physicians use these cells to repair or replace damaged tissues caused by injury, disease, or aging.

Furthermore, treatments for heart problems and joint injuries, skin regeneration, and even the cultivation of organs for transplantation are just a few of the numerous applications for regenerative medicine. The aim is to transform medical interventions by fostering the body's inherent healing capacities and offering inventive resolutions for diverse health issues.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Prevalence of Chronic Illnesses Skyrocket the Sales of Regenerative Medicine?

The rising prevalence of conditions such as cancer, cardiovascular disease, and neurological disorders demands medicine that stands out by offering the potential for disease modification or even cure, addressing the root causes. As a result, the rising prevalence of chronic diseases poses a key driver resulting in a higher trajectory of growth in the Regenerative Medicine Market.

Rapid advancements in gene editing, stem cell engineering, and 3D bioprinting speed up the development of more effective and tailored medicines. These breakthroughs broaden the variety of treatable illnesses, improve treatment precision, and improve overall patient outcomes, propelling regenerative medicine to mainstream healthcare in the market.

Furthermore, growing government support and funding in the research and development of drug discovery are crucial for the expansion of regenerative medicine. There is also a rise in financial support offered by venture capitalists, pharmaceutical corporations, and government agencies in upsurging the productivity of this kind of medicine. In addition to this, financial stability in the pharmaceutical industry is leading to faster clinical studies, larger patient cohorts, and faster market penetration, all of which contribute to bolstering the growth of the Regenerative Medicine Market.

How are High Production Costs and Complex Manufacturing Processes Favoring the Regenerative Medicines Market?

The complexity of the regulatory systems, combined with safety concerns about cell and gene therapies, makes the authorization process lengthy and costly. Thus, stringent restrictions and lengthy approval processes are barriers restraining the growth of the Regenerative Medicine Market.

Due to the high production costs and intricate manufacturing procedures involved in cell and gene therapies, the Regenerative Medicine Market faces considerable challenges in terms of manufacturing and scalability. The fragile nature of the biological components used adds to the challenge, resulting in higher expenses and limited patient access.

Furthermore, the high expense of these therapies limits patient access and puts pressure on healthcare systems. The immature reimbursement policies and the unwillingness of insurance companies to cover the costs considering high upfront expenditures and short-term data of regenerative medicine are key challenges limiting its adoption.

Category-Wise Acumens

Will Prevalence Of Chronic Diseases Upsurge Application of Cell Therapy?

According to VMR, the cell therapy segment is estimated to hold the largest market share in the Regenerative Medicine Market during the forecast period. The targeted therapeutic potential, versatility, and personalized approach are features anticipated to boost the expansion of the market. The expansion and dominance of cell therapy in this rapidly evolving market are further propelled by the compliance of simplified and advanced procedures with a favorable regulatory environment is bolstering the use of cell therapy. In addition to this, the growing aging population susceptible to various diseases is resulting in an increase in healthcare cost, thereby demanding affordable regenerative medicines like cell therapies.

The versatility of cell therapies in treating a wide range of ailments, from cancer and autoimmune disorders to neurological and cardiovascular conditions, expands their market reach and potential impact, contributing to the segment's dominant position. Also, cell therapies differ from conventional pharmaceuticals as they adopt a focused approach to illness therapy, minimizing systemic effects and increasing efficacy while minimizing negative effects.

Furthermore, improvements in cell culture and manufacturing processes contribute toward enhancing the efficiency and scalability of cell therapy production, thereby resulting in higher accessibility and cost-effectiveness. Such technological advancements serve as an important role in bolstering the cell therapy segment in the Regenerative Medicine Market.

Which Factors Enhance the Use of Regenerative Medicine in Musculoskeletal Problems?

The musculoskeletal disorders segment is estimated to dominate in the Regenerative Medicine Market over the period. The high prevalence of this disease is creating a substantial demand for treatment options. Also, active research and development efforts have resulted in an efficient process of new cell and gene therapy applicants, firmly establishing musculoskeletal disorders as a dominant segment in the Regenerative Medicine Market.

Arthritis, osteoarthritis, sports injuries, and back discomfort affect a large proportion of the global population. The prevalence of musculoskeletal problems results in a sizable and expanding patient population, producing a high demand for effective treatment alternatives. As a result, the Regenerative Medicine Market has naturally oriented toward tackling the most common difficulties related to musculoskeletal disorders influencing the demand for regenerative medicine.

Furthermore, the high ailments associated with musculoskeletal diseases are spurring the demand for innovative treatments to relieve symptoms for providing long-term benefits. Thus, regenerative medicine therapies, with their ability to promote tissue repair and regeneration, offer a promising option for treating the underlying causes of many illnesses. This advantage is likely to enable the musculoskeletal disorder segment to dominate the market.

Country/Region-wise Acumens

How will Well-established Healthcare Infrastructure in North America Drive Regenerative Medicine Market?

According to VMR Analyst, North America is estimated to dominate the Regenerative Medicine Market during the forecast period. The dominance of this segment is attributable to the growing demand for personalized medicine with high compatibility with the current regulatory framework.

Also, the growing number of ailments related to the widespread adoption of social habits such as drinking, smoking, dietary changes, and sedentary lifestyles are leading to an increase in healthcare expenditure. This growing number of diseases among the demographic group, especially the aged population, is stirring the need for accurate and efficient regenerative medicines in the region.

A rising number of people are reaching older age groups, leading to an increased incidence of aging-related chronic disorders in the North American region. Regenerative medicine, with its ability to repair and replace damaged tissues, is ideal for the healthcare needs of an aging population, propelling market growth.

Furthermore, the United States Food and Drug Administration (FDA) established streamlined paths for cell and gene therapy approval, promoting faster regulatory approvals and market access. As a result, North America's advantageous regulatory structure, particularly in the United States, is a key driver of the Regenerative Medicine Market in North America.

What are the Key Drivers Influencing the Adoption of Regenerative Medicine in Asia Pacific?

Asia Pacific is estimated to grow at the highest CAGR in the Regenerative Medicine Market during the forecast period due to the high healthcare spending among large and growing patient populations wanting affordable therapies. This growing focus on using regenerative medicines to treat infectious diseases along with the support and funding of government-driven healthcare initiatives is likely to create a dynamic and developing market landscape with tremendous opportunities for innovation and success in this region.

Individuals and governments are increasingly able to invest in innovative and costly medical technology, such as regenerative medicines. This trend is projected to enable the expansion of the market and facilitate the adoption of innovative treatments in the region, propelling the demand for regenerative medicine.

Furthermore, the frequent occurrence of diseases such as hepatitis and dengue fever increases the demand for effective regenerative therapies in this area. Thus, growing awareness regarding the popularity and potential of regenerative medicine in combating diseases among governments and healthcare organizations in combating infectious diseases, resulting in increased investment and research in this field.

Competitive Landscape

The regenerative medicine sector is a battleground for innovation, with established pharmaceutical giants competing for domination alongside dynamic startups. While large firms have extensive portfolios and established distribution networks, versatile startups provide innovative platforms and individualized treatments. This dynamic landscape offers ongoing evolution and ground-breaking discoveries, delivering an exciting ride for both investors and patients.

Some of the prominent players operating in the Regenerative Medicine Market include:

Johnson & Johnson

Novartis

Roche

AbbVie

Pfizer

Vericel Corporation

Cellular Dynamics International, Editas Medicine

Spark Therapeutics

Bluebird bio

Fate Therapeutics

Autolus Therapeutics

Tmunity Therapeutics

Rocket Pharmaceuticals

Carbios Therapeutics

Regentis

Cellular Bioengineering (CBE) Korea

Athersys Inc.

ReNeuron

Histogenics

Regenerative Medicine Market Latest Developments

In January 2024, Vertex Pharmaceuticals has reported promising Phase 2b data for VX-886, a stem cell therapy for pulmonary fibrosis, showing increased lung function and breathing capacity in patients.

In January 2024, Rocket Pharmaceuticals has initiated a Phase 3 trial for its RVL001 stem cell therapy for alpha-1 antitrypsin deficiency (AATD), a rare genetic liver disease, marking a significant step towards commercialization and providing a potentially life-saving treatment for AATD sufferers.

1 INTRODUCTION OF THE GLOBAL REGENERATIVE MEDICINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL REGENERATIVE MEDICINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porter's Five Force Model
4.4 Value Chain Analysis

5 GLOBAL REGENERATIVE MEDICINE MARKET, BY PRODUCT

5.1 Overview
5.2 Therapeutics
5.3 Cell Therapy
- 5.3.1 Stem cell Therapy
- 5.3.2 Cell Transplantations
5.4 Stem cell Therapy Products
5.5 Cell-based Immunotherapy Products
5.6 Gene Therapy
5.7 Tissue Engineering

6 GLOBAL REGENERATIVE MEDICINE MARKET, BY THERAPY AREA

6.1 Overview
6.2 Oncology
6.3 Musculoskeletal Disorders
6.4 Dermatology & Wound Care
6.5 Cardiovascular Diseases
6.6 Ophthalmology
6.7 Neurology
6.8 Other applications

7 GLOBAL REGENERATIVE MEDICINE MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 The U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 The U.K.
- 7.3.3 France
- 7.3.4 Italy
- 7.3.5 Spain
- 7.3.6 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Argentina
- 7.5.3 Rest of LATAM
7.6 Middle East and Africa
- 7.6.1 UAE
- 7.6.2 Saudi Arabia
- 7.6.3 South Africa
- 7.6.4 Rest of the Middle East and Africa

8 GLOBAL REGENERATIVE MEDICINE MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies
8.4 Company Regional Footprint
8.5 Company Industry Footprint
8.6 ACE Matrix

9 COMPANY PROFILES

9.1 Johnson & Johnson
- 9.1.1 Company Overview
- 9.1.2 Company Insights
- 9.1.3 Business Breakdown
- 9.1.4 Product Benchmarking
- 9.1.5 Key Developments
- 9.1.6 Winning Imperatives
- 9.1.7 Current Focus & Strategies
- 9.1.8 Threat from Competition
- 9.1.9 SWOT Analysis
9.2 Novartis
- 9.2.1 Company Overview
- 9.2.2 Company Insights
- 9.2.3 Business Breakdown
- 9.2.4 Product Benchmarking
- 9.2.5 Key Developments
- 9.2.6 Winning Imperatives
- 9.2.7 Current Focus & Strategies
- 9.2.8 Threat from Competition
- 9.2.9 SWOT Analysis
9.3 Roche
- 9.3.1 Company Overview
- 9.3.2 Company Insights
- 9.3.3 Business Breakdown
- 9.3.4 Product Benchmarking
- 9.3.5 Key Developments
- 9.3.6 Winning Imperatives
- 9.3.7 Current Focus & Strategies
- 9.3.8 Threat from Competition
- 9.3.9 SWOT Analysis
9.4 AbbVie
- 9.4.1 Company Overview
- 9.4.2 Company Insights
- 9.4.3 Business Breakdown
- 9.4.4 Product Benchmarking
- 9.4.5 Key Developments
- 9.4.6 Winning Imperatives
- 9.4.7 Current Focus & Strategies
- 9.4.8 Threat from Competition
- 9.4.9 SWOT Analysis
9.5 Pfizer
- 9.5.1 Company Overview
- 9.5.2 Company Insights
- 9.5.3 Business Breakdown
- 9.5.4 Product Benchmarking
- 9.5.5 Key Developments
- 9.5.6 Winning Imperatives
- 9.5.7 Current Focus & Strategies
- 9.5.8 Threat from Competition
- 9.5.9 SWOT Analysis
9.6 Vericel Corporation
- 9.6.1 Company Overview
- 9.6.2 Company Insights
- 9.6.3 Business Breakdown
- 9.6.4 Product Benchmarking
- 9.6.5 Key Developments
- 9.6.6 Winning Imperatives
- 9.6.7 Current Focus & Strategies
- 9.6.8 Threat from Competition
- 9.6.9 SWOT Analysis
9.7 Cellular Dynamics International
- 9.7.1 Company Overview
- 9.7.2 Company Insights
- 9.7.3 Business Breakdown
- 9.7.4 Product Benchmarking
- 9.7.5 Key Developments
- 9.7.6 Winning Imperatives
- 9.7.7 Current Focus & Strategies
- 9.7.8 Threat from Competition
- 9.7.9 SWOT Analysis
9.8 Editas Medicine
- 9.8.1 Company Overview
- 9.8.2 Company Insights
- 9.8.3 Business Breakdown
- 9.8.4 Product Benchmarking
- 9.8.5 Key Developments
- 9.8.6 Winning Imperatives
- 9.8.7 Current Focus & Strategies
- 9.8.8 Threat from Competition
- 9.8.9 SWOT Analysis
9.9 Spark Therapeutics
- 9.9.1 Company Overview
- 9.9.2 Company Insights
- 9.9.3 Business Breakdown
- 9.9.4 Product Benchmarking
- 9.9.5 Key Developments
- 9.9.6 Winning Imperatives
- 9.9.7 Current Focus & Strategies
- 9.9.8 Threat from Competition
- 9.9.9 SWOT Analysis
9.10 Bluebird bio
- 9.10.1 Company Overview
- 9.10.2 Company Insights
- 9.10.3 Business Breakdown
- 9.10.4 Product Benchmarking
- 9.10.5 Key Developments
- 9.10.6 Winning Imperatives
- 9.10.7 Current Focus & Strategies
- 9.10.8 Threat from Competition
- 9.10.9 SWOT Analysis